$238 Million is the total value of Iguana Healthcare Management, LLC's 62 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 281.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PFE | Buy | PFIZER INC | $20,874,000 | +793.6% | 600,000 | +700.0% | 8.78% | +677.8% |
| RARE | Buy | ULTRAGENYX PHARMACEUTICAL IN | $10,866,000 | +395.3% | 175,000 | +250.0% | 4.57% | +331.2% |
| B108PS | New | ACTAVIS PLC | $7,441,000 | – | 25,000 | +100.0% | 3.13% | – |
| IWM | New | ISHARES TRrussell 2000 etf | $6,219,000 | – | 50,000 | +100.0% | 2.62% | – |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $5,903,000 | +211.8% | 25,000 | +150.0% | 2.48% | +171.4% |
| ZBH | Buy | ZIMMER HLDGS INC | $5,876,000 | +107.2% | 50,000 | +100.0% | 2.47% | +80.3% |
| AXDX | Buy | ACCELERATE DIAGNOSTICS INC | $5,625,000 | +485.9% | 250,000 | +400.0% | 2.37% | +409.9% |
| ENDP | New | ENDO INTL PLC | $5,382,000 | – | 60,000 | +100.0% | 2.26% | – |
| HUM | New | HUMANA INC | $5,341,000 | – | 30,000 | +100.0% | 2.25% | – |
| ESRX | New | EXPRESS SCRIPTS HLDG CO | $5,206,000 | – | 60,000 | +100.0% | 2.19% | – |
| STJ | New | ST JUDE MED INC | $4,905,000 | – | 75,000 | +100.0% | 2.06% | – |
| WCG | New | WELLCARE HEALTH PLANS INC | $4,116,000 | – | 45,000 | +100.0% | 1.73% | – |
| CI | New | CIGNA CORPORATION | $3,883,000 | – | 30,000 | +100.0% | 1.63% | – |
| CAH | New | CARDINAL HEALTH INC | $3,611,000 | – | 40,000 | +100.0% | 1.52% | – |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $3,460,000 | +181.5% | 500,000 | +300.0% | 1.46% | +144.9% |
| NVDQ | Buy | NOVADAQ TECHNOLOGIES INC | $3,248,000 | +11.7% | 200,000 | +14.3% | 1.37% | -2.8% |
| MDVN | New | MEDIVATION INC | $3,227,000 | – | 25,000 | +100.0% | 1.36% | – |
| PETX | Buy | ARATANA THERAPEUTICS INC | $3,202,000 | -0.2% | 200,000 | +11.1% | 1.35% | -13.1% |
| ANTM | New | ANTHEM INC | $3,088,000 | – | 20,000 | +100.0% | 1.30% | – |
| TTPH | New | TETRAPHASE PHARMACEUTICALS I | $2,748,000 | – | 75,000 | +100.0% | 1.16% | – |
| LGND | New | LIGAND PHARMACEUTICALS INC | $2,699,000 | – | 35,000 | +100.0% | 1.14% | – |
| ABT | New | ABBOTT LABS | $2,317,000 | – | 50,000 | +100.0% | 0.98% | – |
| FLML | New | FLAMEL TECHNOLOGIES SAsponsored adr | $2,248,000 | – | 125,000 | +100.0% | 0.95% | – |
| HCP | New | HCP INC | $2,161,000 | – | 50,000 | +100.0% | 0.91% | – |
| IMDZ | New | IMMUNE DESIGN CORP | $2,111,000 | – | 100,000 | +100.0% | 0.89% | – |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $1,986,000 | +405.3% | 150,000 | +200.0% | 0.84% | +339.5% |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $1,986,000 | – | 50,000 | +100.0% | 0.84% | – |
| IPCM | New | IPC HEALTHCARE INC | $1,632,000 | – | 35,000 | +100.0% | 0.69% | – |
| CSLT | New | CASTLIGHT HEALTH INCcl b | $1,552,000 | – | 200,000 | +100.0% | 0.65% | – |
| PTCT | New | PTC THERAPEUTICS INC | $1,521,000 | – | 25,000 | +100.0% | 0.64% | – |
| DERM | Buy | DERMIRA INC | $1,228,000 | +35.5% | 80,000 | +60.0% | 0.52% | +18.0% |
| TXMD | New | THERAPEUTICSMD INC | $1,210,000 | – | 200,000 | +100.0% | 0.51% | – |
| KND | New | KINDRED HEALTHCARE INC | $1,190,000 | – | 50,000 | +100.0% | 0.50% | – |
| HAE | New | HAEMONETICS CORP | $1,123,000 | – | 25,000 | +100.0% | 0.47% | – |
| NKTR | New | NEKTAR THERAPEUTICS | $1,100,000 | – | 100,000 | +100.0% | 0.46% | – |
| DBVT | New | DBV TECHNOLOGIES S Asponsored adr | $1,051,000 | – | 45,000 | +100.0% | 0.44% | – |
| PACB | New | PACIFIC BIOSCIENCES CALIF IN | $876,000 | – | 150,000 | +100.0% | 0.37% | – |
| ELGX | Buy | ENDOLOGIX INC | $854,000 | +123.6% | 50,000 | +100.0% | 0.36% | +94.1% |
| TSRO | New | TESARO INC | $574,000 | – | 10,000 | +100.0% | 0.24% | – |
| DEPO | New | DEPOMED INC | $560,000 | – | 25,000 | +100.0% | 0.24% | – |
| TLOG | New | TETRALOGIC PHARMACEUTICALS C | $438,000 | – | 100,000 | +100.0% | 0.18% | – |
| IMMU | New | IMMUNOMEDICS INC | $192,000 | – | 50,000 | +100.0% | 0.08% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2015-06-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC | 17 | Q1 2018 | 7.5% |
| ULTRAGENYX PHARMACEUTICAL IN | 17 | Q1 2018 | 6.7% |
| MERCK & CO INC NEW | 16 | Q1 2018 | 5.4% |
| CELGENE CORP | 15 | Q4 2017 | 7.9% |
| AERIE PHARMACEUTICALS INC | 15 | Q4 2017 | 3.3% |
| GILEAD SCIENCES INC | 14 | Q1 2017 | 6.7% |
| ESPERION THERAPEUTICS INC NE | 14 | Q1 2018 | 7.8% |
| SUPERNUS PHARMACEUTICALS INC | 14 | Q4 2017 | 2.8% |
| DERMIRA INC | 14 | Q1 2018 | 2.7% |
| AMGEN INC | 13 | Q1 2017 | 6.5% |
View Iguana Healthcare Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-16 |
| 13F-HR | 2017-11-14 |
| 13F-HR | 2017-08-14 |
| 13F-HR | 2017-05-15 |
| 13F-HR | 2017-02-14 |
| 13F-HR/A | 2016-11-17 |
| 13F-HR | 2016-11-14 |
| 13F-HR/A | 2016-11-04 |
View Iguana Healthcare Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.